Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma

被引：210

作者：

Chen, Jiang ^{[1
]}

Jin, Renan ^{[1
]}

Zhao, Jie ^{[1
]}

Liu, Jinghua ^{[1
]}

Ying, Hanning ^{[1
]}

Yan, Han ^{[1
]}

Zhou, Senjun ^{[1
]}

Liang, Yuelong ^{[1
]}

Huang, Diyu ^{[1
]}

Liang, Xiao ^{[1
]}

Yu, Hong ^{[1
]}

Lin, Hui ^{[1
]}

Cai, Xiujun ^{[1
]}

机构：

[1] Zhejiang Univ, Dept Gen Surg, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China

来源：

CANCER LETTERS | 2015年 / 367卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Advanced hepatocellular carcinoma (HCC); Epithelial-mesenchymal transitions (EMT) and mesenchymal epithelial transitions (MET); Cancer stem cells (CSCs); Microenvironment; Acquired resistance; EPITHELIAL-MESENCHYMAL TRANSITION; HEDGEHOG SIGNALING PATHWAY; ALPHA-B-CRYSTALLIN; LIVER-CANCER CELLS; PHASE-III; PROMOTES METASTASIS; DEPENDENT MECHANISM; PLUS SORAFENIB; BREAST-CANCER; UP-REGULATION;

D O I：

10.1016/j.canlet.2015.06.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against advanced hepatocellular carcinoma. However, development of resistance to sorafenib has raised concern in recent years due to the high-level heterogeneity of individual response to sorafenib treatment. The resistance mechanism underlying the impaired sensitivity to sorafenib is still elusive though some researchers have made great efforts. Here, we provide a systemic insight into the potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma depending on abundant previous studies and reports. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 11

页数：11

共 50 条

[31] Sorafenib - In hepatocellular carcinoma
Simpson, Dene
Keating, Gillian M.
DRUGS, 2008, 68 (02) : 251 - 258
[32] Molecular and cellular pathology of hepatocellular carcinoma
Ng, IOL
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 : S299 - S303
[33] Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma
Wei, Shuhua
Wei, Fenghua
Li, Mengyuan
Yang, Yuhan
Zhang, Jingwen
Li, Chunxiao
Wang, Junjie
BIOMEDICINE & PHARMACOTHERAPY, 2023, 163
[34] Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma
Xiao, Hong
Chen, Hangyu
Zhang, Lei
Duolikun, Maimaitiyasen
Zhen, Baixin
Kuerban, Subinuer
Li, Xuehui
Wang, Yuxi
Chen, Long
Lin, Jian
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
[35] MiRNA Expression Profiling of Sorafenib Response and Resistance in Hepatocellular Carcinoma
Yousef, George
Butz, Henriett
Kerbel, Robert
Mozes, Roy
Patocs, Attila
Kerbel, Robert
LABORATORY INVESTIGATION, 2015, 95 : 200A - 201A
[36] Galectin-1 modulates sorafenib resistance in hepatocellular carcinoma
Tung, Hsu W.
Su, Yen H.
Chiu, Ching F.
Chen, Hsin A.
Shen, Shing C.
CANCER SCIENCE, 2022, 113 : 1058 - 1058
[37] Regorafenib but not sorafenib suppresses ERK signaling in human hepatocellular carcinoma acquiring sorafenib resistance
Hashiba, Tomomi
Yamashita, Taro
Okada, Hikari
Hayashi, Takehiro
Yoshida, Mariko
Sunagozaka, Hajime
Honda, Masao
Kaneko, Shuichi
HEPATOLOGY, 2016, 64 : 248A - 248A
[38] Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
Zeng, Zhi
Lu, Qiliang
Liu, Yang
Zhao, Junjun
Zhang, Qian
Hu, Linjun
Shi, Zhan
Tu, Yifeng
Xiao, Zunqiang
Xu, Qiuran
Huang, Dongsheng
FRONTIERS IN ONCOLOGY, 2021, 11
[39] Unraveling metabolic vulnerabilities to counteract sorafenib resistance in hepatocellular carcinoma
Pedretti, S.
Palermo, F.
Tomaiuolo, P.
Imperato, G.
Braghin, M.
Celikag, M.
Crestani, M.
De Fabiani, E.
Mitro, N.
FEBS OPEN BIO, 2024, 14 : 29 - 29
[40] YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin
Ting Sun
Wenhao Mao
Hui Peng
Qi Wang
Lin Jiao
Cellular Oncology, 2021, 44 : 689 - 699

← 1 2 3 4 5 →